Drug intelligence / Profile preview

LycOmega

Development stage: Preclinical
Lead developer: Lycotec
Modality: Small Molecules
Administration: Oral

Overview

**LycOmega** is a Lycotec pipeline drug candidate described as an **Omega-3-based small molecule** being developed for lipid abnormalities, specifically **elevated triglycerides** and **elevated LDL**. Publicly available pipeline information identifies Lycotec as the developer and places the program at an **early pharmacokinetics and pharmacodynamics / preclinical stage**. No specific molecular target, defined receptor-level mechanism, formulation details, route of administration, or manufacturing partner were identified in the provided source material.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ALOX12 (Arachidonate 12-lipoxygenase, 12S type)ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on LycOmega.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LycOmega.

Explore the full profile